US Patent 9861624 Method of treating cancer
Patent 9861624 was granted and assigned to Exelixis on January, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 21 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Article (+190 characters)
Article
Patent abstract
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteolytic bone metastases, with a dual inhibitor of MET and VEGF.
Edits on 1 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Dana T. Aftab0
Edits on 20 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09861624 Method of treating cancer US Patent 9861624 Method of treating cancer
Infobox
Patent Number
09861624
Patent Number
9861624
Edits on 16 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09861624 Method of treating cancer
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09861624
Date of patent
January 9, 2018
Patent application number
14398188
Date Filed
May 2, 2013
Patent primary examiner
Find more entities like US Patent 9861624 Method of treating cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
